| HOME >> MEDICINE >> TECHNOLOGY |
Table 32: Top Partnership Deal Terminations, Merck-Portola Licensing Agreement, Deal Value ($m), 2009 61
Table 33: Top Partnership Deal Terminations, Clinical Trial Details, Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme, 2007-2011 65
Table 34: Top Partnership Deal Terminations, Clinical Trial Details, Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery, 2007-2013 65
Table 35: Top Partnership Deal Terminations, Clinical Trial Details, Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas, 2011-2012 66
Table 36: Top Partnership Deal Terminations, Pfizer-Celldex Licensing Agreement, Deal Value ($m), 2008 66
Table 37: Top Partnership Deal Terminations, Clinical Trial Details, Safety and Efficacy of Gabapentin in Diabetic Peripheral Neuropathy, 2006 70
Table 38: Top Partnership Deal Terminations, Clinical Trial Details, Safety and Efficacy of Gabapentin in Postherpetic Neuralgia, 2006-2007 71
Table 39: Top Partnership Deal Terminations, Clinical Trial Details, Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women, 2007-2008 71
Table 40: Top Partnership Deal Terminations, Clinical Trial Details, Safety and Efficacy of Gabapentin in Postherpetic Neuralgia, 2008-2009 72
Table 41: Top Partnership Deal Terminations, Clinical Trial Details, Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women, 2008-2009 72
Table 42: Top Partnership Deal Terminations, Abbott-Depomed Licensing Agreement, Deal Value (
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |